On the effects of CP 55-940 and other cannabinoid receptor agonists in C6 and U373 cell lines

Toxicology in Vitro

Volumn 29, Issue 7, 2015, Pages 1941-1951

  Ortega, A ^a   Rangel Lopez E ^a   Hidalgo Miranda, A ^a   Morales, A ^a   Ruiz Garcia E ^a   Meneses Garcia A ^a   Herrera Gomez A ^a   Aguilar Ponce, J L ^a   Gonzalez Herrera I G ^a   Guevara Salazar, P ^a   Prospero Garcia O ^b   Del Angel, S A ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antiproliferative activity; Apoptosis; Cannabinoids; Glial tumors

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZOXAZINE DERIVATIVE; CANNABINOID; CYCLOHEXANOL DERIVATIVE; DNA; ENDOCANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG SELECTIVITY; DRUG STRUCTURE; GLIOMA CELL LINE; HUMAN; HUMAN CELL; NEWBORN; NONHUMAN; RAT; ANIMAL; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; APOPTOSIS; ARACHIDONIC ACIDS; ASTROCYTES; BENZOXAZINES; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CYCLOHEXANOLS; DNA; ENDOCANNABINOIDS; HUMANS; MORPHOLINES; NAPHTHALENES; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR;

EID: 84940068665     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2015.08.003     Document Type: Article

References (52)

1. Amar M.B. Cannabinoids in medicine: a review of their therapeutical potential. J. Ethnopharmacol. 2006, 105:1-25.
2. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2015. http://atlasgeneticsoncology.org/Genes/EGR1ID496ch5q31.html.
3. Baron V., Adamson E.D., Calogero A., Ragona G., Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53 and fibronectin: Egr1 is a potential target of gene therapy for prostate cancer. Cancer Gene Ther. 2006, 13:115-124.
4. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., De Petrocellis L., Di Marzo V. Control by the endogenous cannabionoid system of ras oncogene-dependent tumor growth. FASEB J. 2001, 15:2745-2747.
5. Blazquez C., Carracedo A., Barrado L., Real P.J., Fernandez-Luna J.L., Velasco G., Malumbres M., Guzman M. Cannabonoid receptors as a novel target for the treatment of melanoma. FASEB J. 2006, 20:2633-2635.
6. Blazquez C., Salazar M., Carracedo A., Lorente M., Egia A., González-Feria L., Haro A., Velasco G., Guzmán M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase 2 expression. Cancer Res. 2008, 68:1945-1952.
7. Bouaboula M., Poinot-Chazel C., Bourrié B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., Casellas P. Activation of mitogen activated protein kinase by stimulation of the central cannabinoid receptor CB1. Biochem. J. 1995, 312:637-641.
8. Bouaboula M., Bourrié B., Rinaldi-Carmona M., Shire D., Le Fur G., Casellas P. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 1995, 270:13973-13980.
9. Breivogel C.S., Griffin N.G., Di Marzo V., Martin B.R. Evidence for a new G protein- coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001, 60:155-163.
10. Burnet N.G., Lynch A.G., Jefferies S.J., Price S.J., Jones P.H., Antoun N.M., Xuereb J.H., Pohl U. High grade gliomas: imaging combined with pathological grade defines management and predicts prognosis. Radiother. Oncol. 2007, 85:371-378.
11. Carracedo A., Gironella M., Lorente M., García S., Guzman M., Velasco G., Iovanna J.L. Cannabinoids induced apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006, 66:6748-6755.
12. Carracedo A., Lorente M., Egia A., Blázquez C., García S., Giroux V., Malicet C., Villuendas R., Gironella M., González-Feria L., Piris M.A., Iovanna J.L., Guzmán M., Velasco G. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006, 9:301-312.
13. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., Jorcano J.L., Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoids receptors. J. Clin. Invest. 2003, 111:43-50.
14. Derkinderen P., Toutant M., Burgaya F., Le Bert M., Siciliano J.C., De Franciscis V., Gelma M., Girault J.A. Regulation or a neuronal form of focal adhesion kinase by anandamide. Science 1996, 273:1719-1722.
15. Ellert-Miklaszewska A., Kaminska B., Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 2005, 17:25-37.
16. Fernandez-Ruiz J., Romero J., Velasco G., Tolon R., Ramos J., Guzman M. Cannabinoid CB2 receptor: a new target for controlling neuronal cell survival?. Trends Pharmacol. Sci. 2007, 28:83-92.
17. Fowler C. Overview on the pharmacology of the endocannabinoid system. Mol. Neurobiol. 2007, 36:15-25.
18. Galve-Roperh I., Aguado T., Palazuelos J., Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 2008, 14:2279-2288.
19. Galve-Roperh I., Sanchez C., Cortes M.L., Gómez del Pulgar T., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 2000, 6:313-319.
20. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constitutent of hashish. J. Am. Chem. Soc. 1964, 86:1646-1647.
21. Gomez del Pulgar T., Velasco G., Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 2000, 347:369-373.
22. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer. 2003, 3:745-755.
23. Hall W., Christine M., Currow D. Cannabionoids and cancer: causation, remediation and palliation. Lancet Oncol. 2005, 6:35-42.
24. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
25. Hudson B.D., Hebert T.E., Kelly M.E. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol. Pharmacol. 2010, 77:1-9.
26. Jacobson S.O., Wallin T., Fowler C. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 2001, 299:951-952.
27. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Shatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 1992, 4:736-742.
28. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002, 61:215-225.
29. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 2006, 318:1375-1387.
30. Liu J., Gao B., Mirshahi F., Sanyal A.J., Khanolar A.D., Makriyannis A., Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 2000, 346:835-840.
31. Liu J., Grogan L., Nau M.M., Allegra C.J., Chu E., Wright J.J. Physical interaction between p53 and primary response gene Egr-1. Int. J. Oncol. 2001, 18:863-870.
32. Maher E.A., Furnari F.B., Bachoo R.M., Rowith D.H., Louis D.N., Cavenee W.K., DePinho R.A. Malignat glioma: genetics and biology of a grave matter. Genes Dev. 2001, 15:1311-1333.
33. Makriyannis A., Mechoulam R., Piomelli D. Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology 2005, 48:1061-1071.
34. Matsuda L.A., Lolait S.J., Browstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional receptor and expression of the clones cDNA. Nature 1990, 346:561-564.
35. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., Nagarkatti P.S. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002, 100:627-634.
36. Morán J., Patel J. Stimulation of N-Methyl-D-Aspartate receptor promotes the biochemical differentiation of cerebellar granule neurons and not astrocytes. Brain Res. 1989, 486:15-25.
37. Moos P.J., Fitzpatrick F.A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3896-3901.
38. Munro S., Thomas T.L., Abbu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
39. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., Carchman R.A. Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst. 1975, 55:597-602.
40. Piomelli D. The molecular logic of endocannabinoid signaling. Nat. Rev. Neurosci. 2003, 4:873-884.
41. Ramer R., Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 2008, 100:59-69.
42. Ramos J., Gómez Ruíz M., Hernández M., De Miguel R. Overview of the biochemistry of the cannabinoid system. Mol. Neurobiol. 2007, 36:3-14.
43. Rangel-López E., Colín-González A.L., Paz-Loyola A.L., Pinzón E., Torres I., Serratos I.N., Castellanos P., Wajner M., Souza D.O., Santamaría A. Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain. Neuroscience 2015, 285:97-106.
44. 3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 1996, 58:1239-1247.
45. Rueda D., Galve-Ropher I., Haro A., Guzman M. The CB1 cannabinoid receptor is coupled to the activation of C-jun N-terminal kinase. Mol. Pharmacol. 2000, 58:814-820.
46. Salazar M., Carracedo A., Salanueva I.J., Hernández-Tiedra S., Lorente M., Egia A., Vázquez P., Blázquez C., Torres S., García S., Nowak J., Fimia G.M., Piacentini M., Cecconi F., Pandolfi P.P., González-Feria L., Iovanna J.L., Guzmán M., Boya P., Velasco G. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 2009, 119:1359-1372.
47. Sanchez C., de Ceballos M.L., del Pulgar T.G., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Ramon y Cajal S., Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 2001, 61:5784-5789.
48. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008, 68:339-342.
49. Schor N.F. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Therap. 2009, 121:253-264.
50. Tomiyama K., Funada M. Cytotoxicity of synthetic cannabinoids found in 'Spice' products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol. Lett. 2011, 207:12-17.
51. Walsh D., Nelson K.A., Manmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Suppl. Care Cancer. 2003, 11:137-143.
52. Zhuang S.Y., Bridges D., Grigorenko E., McCloud S., Boon A., Hampson R.E., Deadwyler S.A. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 2005, 48:1086-1096.